Beneficial Effects of a Soy-Based Dietary Supplement on Lipid Levels and Cardiovascular Risk Markers in Type 2 Diabetic Subjects
L.H. is on the Board of Directors of, is paid consulting fees by, and holds stock in Nutri Pharma ASA. Abbreviations: apo, apolipoprotein; BP, blood pressure; CAD, coronary artery disease; ELISA, enzymelinked immunosorbent assay; Lp(a), lipoprotein(a); PAI-1, plasminogen activator inhibitor 1. A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances. OBJECTIVE -Consumption of soy protein has recently been shown to improve
... the blood lipid levels in nondiabetic subjects. The purpose of this study was to evaluate if a dietary supplement of soy protein, isoflavones, and cotyledon fiber (Abalon) affects cardiovascular risk markers, blood glucose, and insulin levels in type 2 diabetic subjects. RESEARCH DESIGN AND METHODS -Twenty type 2 diabetic subjects participated in a crossover trial. They were randomized to double-blind supplementation for 6 weeks with Abalon (soy protein [50 g/day] with high levels of isoflavones [minimum 165 mg/day] and cotyledon fiber [20 g/day]) or placebo (casein [50 g/day] and cellulose [20 g/day]), separated by a 3-week wash-out period. RESULTS -The results are expressed as means ± SD. The percentage mean treatment difference between Abalon and placebo demonstrated significantly lower mean values after Abalon for LDL cholesterol (10 ± 15%, P Ͻ 0.05), LDL/HDL ratio (12 ± 18%, P Ͻ 0.05), apolipoprotein (apo) B100 (30 ± 38%, P Ͻ 0.01), triglycerides (22 ± 10%, P Ͻ 0.05), and homocysteine (14 ± 21%, P Ͻ 0.01), whereas the total cholesterol value tended to be less significant but still lower (8 ± 15%, P Ͻ 0.08). No change occurred in HDL cholesterol, apo B100/apo A1 ratio, plasminogen activator inhibitor 1, factor VIIc, von Willebrand factor, fibrinogen, lipoprotein(a), glucose, HbA 1c , or 24-h blood pressure. CONCLUSIONS -These results indicate beneficial effects of dietary supplementation with Abalon on cardiovascular risk markers in type 2 diabetic subjects. This improvement is seen even in individuals with near-normal lipid values.